Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.
Some MDS patients with very poor genetics do better after transplant than expected, suggesting transplant may still benefit those previously deemed unsuitable.
EBMT registry analysis identifies a subgroup of MDS patients with very poor-risk cytogenetics that demonstrates relatively more favorable outcomes after allo-HCT compared to other very poor-risk subgroups, suggesting allo-HCT should not be categorically withheld based solely on cytogenetic risk.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- clinical
- Journal
- American Journal of Hematology
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.